MENLO PARK, CA / ACCESSWIRE / October 30, 2023 / Clearblow, an AI healthcare tech startup focused on developing smart solutions for respiratory health, today announced the successful completion of its preseed financing round. This funding round was led by Global Venture Capital Partners and angel investor David McCarthy.
Founded in February 2021 by Lach Black, Clearblow introduces an intelligent pocket spirometer that empowers both adults and children to proactively manage their respiratory health. Spirometry testing plays a pivotal role in tracking lung function, quantifying the volume of air inhaled and exhaled during a single forced breath. The company has designed a sophisticated Bluetooth-enabled portable device, which translates exhaled air into an acoustic signal. A cutting-edge algorithm extracts spirometric data, analyzes the test results, and generates predictions that contribute to enhanced patient management and outcomes.
The infusion of capital will be directed towards the expansion of Clearblow's team, establishing the company's product development initiatives and increasing its efforts in commercialization. Additionally, Clearblow will cultivate its strategic partnerships with research hospitals, pharmaceutical firms, insurance providers, and healthcare professionals. An ambitious agenda is also in place to expedite the FDA clearance process, facilitating the use of its portable spirometer for remote monitoring and diagnosis of COVID-19 patient symptoms.
"Clearblow is dedicated to crafting intelligent technology that empowers individuals grappling with chronic lung conditions to gain a stronger grip on their respiratory well-being," said founder and CEO Lach Black. "We're excited to collaborate with early investors who share our enthusiasm for remote telehealth solutions aimed at managing lung conditions."
Clearblow's digital spirometer offers patients the convenience of accurately conducting the same lung function test that is traditionally performed in a medical setting, all from the comfort of their homes. Users can easily access their FEV1% scores, enabling them to monitor any fluctuations and ensure they remain within the parameters established by their healthcare providers. The device seamlessly syncs with a smart app for comprehensive lung health assessment. Beyond measuring FEV1 and PEF data, the app facilitates symptom tracking, medication monitoring, and direct data sharing with the patient's primary care physician.
In response to the successful seed funding round, Alex Beecham, partner at Global VC Partners, said, "Clearblow's dedication to smart respiratory solutions aligns with our vision of leveraging technology to enhance healthcare. We believe their innovative approach will reshape how patients and healthcare providers manage lung conditions, and we are excited to be part of this journey."
About Clearblow:
Clearblow is at the forefront of smart spirometry technology, serving the needs of healthcare providers and individuals coping with chronic respiratory conditions. Clearblow simplifies remote lung function testing, enhancing accuracy and enabling early detection of declining lung health, thereby furnishing doctors with valuable data to optimize patient care. Clearblow's stylish and intelligent Bluetooth-enabled spirometer offers live feedback throughout lung function tests via an intuitive LED display, haptic vibration, and a user-friendly mobile app. Test results can be conducted remotely and seamlessly shared in real-time with the patient's primary care physician, enhancing testing accuracy and contributing to improved patient outcomes. Learn more atwww.clearblow.com and follow up on social media (LinkedIn).
Media Details:
Company Name: Clearblow
Contact Person: Olivia Zhu
Business Mail: [email protected]
City and Country: Menlo Park, California
Website: http://www.clearblow.com
SOURCE: Clearblow